{"product_id":"the-esmo-gynaecological-cancers-congress-2023","title":"The ESMO Gynaecological Cancers Congress 2023","description":"\u003cspan style=\"color: #1b1919; font-size: 24px;\"\u003eThe ESMO Gynaecological Cancers Congress 2023\u003c\/span\u003e has become an essential annual appointment for oncology professionals treating patients with such malignancies – the place to learn the latest promising news, acquire high quality education and exchange ideas.\u003cbr\u003e\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cspan style=\"color: #1b1919; font-size: 24px;\"\u003e took place onsite in Barcelona, on 23-24 February 2023, and online, through a virtual platform.\u003c\/span\u003e\n\u003cbr\u003e\u003cul\u003eThis edition featured the innovative LIVE Plus format, which provided a wealth of opportunities for exchange of ideas among delegates.\u003c\/ul\u003e\n\u003cdiv class=\"ezxmltext-field\"\u003e\n\u003cbr\u003e\u003cbr\u003eAt this event, delegates had the chance to learn about practice challenges and controversies, brainstorm with peers and explore further opportunities to advance their careers.\u003cbr\u003e\u003cbr\u003eESMO Gynaecological Cancers has become an essential annual appointment for oncology professionals treating patients with such malignancies – the place to learn the latest promising news, acquire high quality education and exchange ideas.\u003cbr\u003e\u003ch3\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003cdl\u003e\n\u003cdt\u003eStart date 23 Feb 2023\u003c\/dt\u003e\n\u003cdt\u003eEnd date 24 Feb 2023\u003c\/dt\u003e\n\u003cdt\u003eLocation Barcelona, Spain\u003c\/dt\u003e\n\u003cdt\u003e\u003c\/dt\u003e\n\u003c\/dl\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch3\u003eESMO Gynaecological Cancers Scientific Co-Chairs\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eSusana Banerjee\u003c\/strong\u003e, London, UK\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDomenica Lorusso\u003c\/strong\u003e, Rome, IT\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBradley J. Monk\u003c\/strong\u003e, Phoenix, AZ, USA\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eScientific Committee Members\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eRobert Coleman\u003c\/strong\u003e, Houston, TX, USA\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNicole Concin\u003c\/strong\u003e, Innsbruck, Austria\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKosei Hasegawa\u003c\/strong\u003e, Saitama, Japan\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAna Oaknin\u003c\/strong\u003e, Barcelona, Spain\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIsabelle Ray-Coquard\u003c\/strong\u003e, Lyon, France\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e \u003cbr\u003e\u003ch2\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eADCs in gynaecological cancers Introduction.mp4\u003c\/li\u003e\n\u003cli\u003eADCs in gynaecological cancers Q\u0026amp;A.mp4\u003c\/li\u003e\n\u003cli\u003eADCs in gynaecological cancers Role of ADCs in cervical cancer treatment in the era of immunotherapy.mp4\u003c\/li\u003e\n\u003cli\u003eADCs in gynaecological cancers Role of ADCs in cervical cancer treatment in the era of immunotherapy.pdf\u003c\/li\u003e\n\u003cli\u003eADCs in gynaecological cancers The evolving ADC treatment landscape in ovarian cancer.mp4\u003c\/li\u003e\n\u003cli\u003eADCs in gynaecological cancers The evolving ADC treatment landscape in ovarian cancer.pdf\u003c\/li\u003e\n\u003cli\u003eADCs in gynaecological cancers The new challenge ADC class effects, on off-target adverse reactions and their interdisciplinary management.mp4\u003c\/li\u003e\n\u003cli\u003eADCs in gynaecological cancers The new challenge ADC class effects, on off-target adverse reactions and their interdisciplinary management.pdf\u003c\/li\u003e\n\u003cli\u003eADCs in gynaecological cancers Understanding the basics Structure, key properties, mechanism of action, optimal diagnostic test to determine the\u003c\/li\u003e\n\u003cli\u003etarget.mp4\u003c\/li\u003e\n\u003cli\u003eADCs in gynaecological cancers Understanding the basics Structure, key properties, mechanism of action, optimal diagnostic test to determine the\u003c\/li\u003e\n\u003cli\u003etarget.pdf\u003c\/li\u003e\n\u003cli\u003eAstraZeneca – Long-term survival Evidence from first-line PARPi maintenance trials.mp4\u003c\/li\u003e\n\u003cli\u003eAstraZeneca – Long-term survival Integrating the latest data into clinical practice.mp4\u003c\/li\u003e\n\u003cli\u003eAstraZeneca – Long-term survival Welcome and introduction.mp4\u003c\/li\u003e\n\u003cli\u003eEndometrial cancer Beyond immunotherapy What is the role of HER2, p53 and other molecular targets in the recurrent.mp4\u003c\/li\u003e\n\u003cli\u003eEndometrial cancer Beyond immunotherapy What is the role of HER2, p53 and other molecular targets in the recurrent.pdf\u003c\/li\u003e\n\u003cli\u003eEndometrial cancer Introduction.mp4\u003c\/li\u003e\n\u003cli\u003eEndometrial cancer Introduction.pdf\u003c\/li\u003e\n\u003cli\u003eEndometrial cancer Is immunotherapy changing the face of recurrent metastatic endometrial cancer.mp4\u003c\/li\u003e\n\u003cli\u003eEndometrial cancer Is immunotherapy changing the face of recurrent metastatic endometrial cancer.pdf\u003c\/li\u003e\n\u003cli\u003eEndometrial cancer Q\u0026amp;A.mp4\u003c\/li\u003e\n\u003cli\u003eEndometrial cancer Revisiting the adjuvant therapy in endometrial cancer ESMO Guidelines.mp4\u003c\/li\u003e\n\u003cli\u003eEndometrial cancer Revisiting the adjuvant therapy in endometrial cancer ESMO Guidelines.pdf\u003c\/li\u003e\n\u003cli\u003eESMO Colloquium supported Concluding remarks.mp4\u003c\/li\u003e\n\u003cli\u003eESMO Colloquium supported Emerging molecular profiling models for advanced endometrial cancer.mp4\u003c\/li\u003e\n\u003cli\u003eESMO Colloquium supported Introduction.mp4\u003c\/li\u003e\n\u003cli\u003eESMO Colloquium supported Q\u0026amp;A.mp4\u003c\/li\u003e\n\u003cli\u003eESMO Colloquium supported Research insights- New immunotherapy combinations in clinical development for gynecological malignancies.mp4\u003c\/li\u003e\n\u003cli\u003eESMO Colloquium supported The landscape of approved immune checkpoint inhibitors and TKI combinations in advanced endometrial cancer.mp4\u003c\/li\u003e\n\u003cli\u003efinal_programme_gynae23hybrid.pdf\u003c\/li\u003e\n\u003cli\u003eGSK – Shifting the treatment paradigm of OC EC Live Q\u0026amp;A and discussion.mp4\u003c\/li\u003e\n\u003cli\u003eGSK – Shifting the treatment paradigm of OC EC Where are we going with EC- Aiming to improve outcomes in primary advanced or recurrent.mp4\u003c\/li\u003e\n\u003cli\u003eGSK – Shifting the treatment paradigm of OC EC Where are we going with OC- Evolving the management of 1L.mp4\u003c\/li\u003e\n\u003cli\u003eGSK – Shifting the treatment paradigm of OC EC Where are we now- Latest advances in treatment of gynecologic cancer.mp4\u003c\/li\u003e\n\u003cli\u003eHow hot is HIPEC treatment in ovarian cancer HIPEC is not IT (CON).pdf\u003c\/li\u003e\n\u003cli\u003eHow hot is HIPEC treatment in ovarian cancer Introduction and first vote.mp4\u003c\/li\u003e\n\u003cli\u003eHow hot is HIPEC treatment in ovarian cancer Introduction and first vote.pdf\u003c\/li\u003e\n\u003cli\u003eHow hot is HIPEC treatment in ovarian cancer Second vote and conclusions.mp4\u003c\/li\u003e\n\u003cli\u003eHow hot is HIPEC treatment in ovarian cancer Second vote and conclusions.pdf\u003c\/li\u003e\n\u003cli\u003eHow hot is HIPEC treatment in ovarian cancer The data absolutely support integration of HIPEC into primary ovarian cancer management (PRO).mp4\u003c\/li\u003e\n\u003cli\u003eHow hot is HIPEC treatment in ovarian cancer The data absolutely support integration of HIPEC into primary ovarian cancer management (PRO).pdf\u003c\/li\u003e\n\u003cli\u003eHow to interpret overall survival data with PARP inhibitors Is there a biological rationale to support decremental impact on overall survival.mp4\u003c\/li\u003e\n\u003cli\u003eHow to interpret overall survival data with PARP inhibitors Is there a biological rationale to support decremental impact on overall survival.pdf\u003c\/li\u003e\n\u003cli\u003eHow to interpret overall survival data with PARP inhibitors Is there clinical evidence to support the link between PARPi use and a negative impact on OS.mp4\u003c\/li\u003e\n\u003cli\u003eHow to interpret overall survival data with PARP inhibitors Is there clinical evidence to support the link between PARPi use and a negative impact on OS.pdf\u003c\/li\u003e\n\u003cli\u003eHow to interpret overall survival data with PARP inhibitors Q\u0026amp;A.mp4\u003c\/li\u003e\n\u003cli\u003eHow to interpret overall survival data with PARP inhibitors Why are we having this Symposium Recent regulatory actions by FDA.mp4\u003c\/li\u003e\n\u003cli\u003eHow to interpret overall survival data with PARP inhibitors Why are we having this Symposium Recent regulatory actions by FDA.pdf\u003c\/li\u003e\n\u003cli\u003eIs cervical cancer still an orphan disease Immunotherapy in cervical cancer A paradigm shift.mp4\u003c\/li\u003e\n\u003cli\u003eIs cervical cancer still an orphan disease Immunotherapy in cervical cancer A paradigm shift.pdf\u003c\/li\u003e\n\u003cli\u003eIs cervical cancer still an orphan disease Innovative techniques in radiation oncology to increase cure and reduce toxicity.mp4\u003c\/li\u003e\n\u003cli\u003eIs cervical cancer still an orphan disease Innovative techniques in radiation oncology to increase cure and reduce toxicity.pdf\u003c\/li\u003e\n\u003cli\u003eIs cervical cancer still an orphan disease Molecular profiling and pathology of cervical cancer patients.mp4\u003c\/li\u003e\n\u003cli\u003eIs cervical cancer still an orphan disease Molecular profiling and pathology of cervical cancer patients.pdf\u003c\/li\u003e\n\u003cli\u003eIs cervical cancer still an orphan disease Q\u0026amp;A.mp4\u003c\/li\u003e\n\u003cli\u003eKeynote address Introduction to the Keynote lecture.mp4\u003c\/li\u003e\n\u003cli\u003eKeynote address Pandemomics Challenging assumptions in gynecologic oncology.mp4\u003c\/li\u003e\n\u003cli\u003eKeynote address Pandemomics Challenging assumptions in gynecologic oncology.pdf\u003c\/li\u003e\n\u003cli\u003eMini Oral session 1MO – Identification of RAD51 foci in cancer-associated circulating cells and their association.mp4\u003c\/li\u003e\n\u003cli\u003eMini Oral session 1MO – Identification of RAD51 foci in cancer-associated circulating cells and their association.pdf\u003c\/li\u003e\n\u003cli\u003eMini Oral session 22MO – Homologous Recombination Gene Mutations in Uterine Serous Cancer.mp4\u003c\/li\u003e\n\u003cli\u003eMini Oral session 22MO – Homologous Recombination Gene Mutations in Uterine Serous Cancer.pdf\u003c\/li\u003e\n\u003cli\u003eMini Oral session 36MO – Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC).mp4\u003c\/li\u003e\n\u003cli\u003eMini Oral session 36MO – Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC).pdf\u003c\/li\u003e\n\u003cli\u003eMini Oral session 37MO – Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer.mp4\u003c\/li\u003e\n\u003cli\u003eMini Oral session 37MO – Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer.pdf\u003c\/li\u003e\n\u003cli\u003eMini Oral session 39MO – Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer.mp4\u003c\/li\u003e\n\u003cli\u003eMini Oral session 39MO – Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer.pdf\u003c\/li\u003e\n\u003cli\u003eMini Oral session 40MO – Targetable Gene Mutations in Mucinous Ovarian Cancer.mp4\u003c\/li\u003e\n\u003cli\u003eMini Oral session 40MO – Targetable Gene Mutations in Mucinous Ovarian Cancer.pdf\u003c\/li\u003e\n\u003cli\u003eMini Oral session 74MO – Clinical outcomes for pelvic node-positive vulvar carcinoma in the PET and IMRT era.mp4\u003c\/li\u003e\n\u003cli\u003eMini Oral session 74MO – Clinical outcomes for pelvic node-positive vulvar carcinoma in the PET and IMRT era.pdf\u003c\/li\u003e\n\u003cli\u003eMini Oral session Invited Discussant of abstracts 22MO, 38MO, 39MO and 1MO.mp4\u003c\/li\u003e\n\u003cli\u003eMini Oral session Invited Discussant of abstracts 22MO, 38MO, 39MO and 1MO.pdf\u003c\/li\u003e\n\u003cli\u003eMini Oral session Invited Discussant of abstracts 36MO and 37MO.mp4\u003c\/li\u003e\n\u003cli\u003eMini Oral session Invited Discussant of abstracts 36MO and 37MO.pdf\u003c\/li\u003e\n\u003cli\u003eMini Oral session Invited Discussant of abstracts 40MO and 74MO.mp4\u003c\/li\u003e\n\u003cli\u003eMini Oral session Invited Discussant of abstracts 40MO and 74MO.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 10P – Neoadjuvant chemotherapy with bevacizumab for IIb stage cervical cancer.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 11P – Conization before radical hysterectomy in early cervical cancer A Korean multi-center study.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 12P – Tisotumab vedotin in recurrent or metastatic cervical cancer.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 13P – Cervical cancer screening in a Basic Health Unit in South of Brazil impact of the COVID-19 pandemic.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 14P – Clinical Outcomes Of Women Who Attend The Cameroon Baptist Convention Health Services.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 15P – Efficacy and safety analysis of recombinant human endostatin (Endostar).pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 16P – Impact of Preoperative versus Postoperative radiotherapy and radical hysterectomy without systemic.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 17P – Impact of adjuvant chemoradiotherapy on survival outcome compared to other treatment modalities for cervical cancer stage IIIc.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 18P – Prospective Randomized Comparison of Quality of Life in Locally Advanced Cervical Cancer treated with Intracavitary or Interstitial Brachytherapy.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 19P – Neoadjuvant chemotherapy followed by radical surgery vs chemoradiotherapy in patients with cervical cancer (stage IIB, FIGO 2018).pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 20P – Randomized Comparison of four Radiotherapy schedules in locally advanced cervical cancer A Prospective study.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 21TiP – Molecular Alterations Predictive of Outcome in Early Staged Cervical Cancer.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 23P – Pre-treatment inflammatory indexes predict the clinical outcome of patients with endometrial cancer a MITO24 study.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 24P – A phase II trial of Docetaxel cisplatin chemotherapy followed by pelvic radiation therapy.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 25P – Prognostic classification of endometrial cancer according to transcriptomic-based immunophenotype.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 26P – Demographics and survival outcomes in patients (pts) with advanced or recurrent (A R) endometrial cancer (EC) in the English real-world (RW) setting.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 27P – Treatment Outcomes and Toxicity Profiles in South Asian patients of High-Risk Endometrial Cancer treated with PORTEC-3 trial regimen.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 28P – Clinicopathologic characteristics and oncologic outcomes of mismatch repair-deficient microsatellite instability-high endometrial cancer.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 29P – Outcomes of patients with intermediate-high risk early stage endometrial cancer after surgery according to adjuvant treatment.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 2P – Outcomes of patients with gynecological tumors harboring HER2 defects.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 30P – Validation of MODEPLEX technology for the determination of POLE hotspot mutations in endometrial carcinoma samples.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 31P – Uterine Cancer Metastasis Patterns and Racial Disparities A SEER Database Population Study 2010-2019.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 3P – NaPi2b Expression in High Grade Serous Ovarian Cancer results from combined data sets.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 41P – Phase 1 analysis of ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 42P – Efficacy of maintenance with PARPi in advanced ovarian cancer according to the location of BRCA mutation.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 43P – Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC).pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 44P – Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in patients with recurrent ovarian cancer.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 45P – MITO39 Effiacy and tolerability of PLD-Trabectedin in the treatment of relapsed Ovarian Cancer after maintenance therapy with PARP-i.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 46P – Long-term residual chemotherapy-induced peripheral neuropathy (CIPN) and relationship with single nucleotides polymorphisms (SNPs).pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 47P – Platinum rechallenge (PtRc) for high-grade epithelial ovarian cancer (HGEOC) patients (pts) considered not eligible for further platinum therapy.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 48P – Response to chemotherapy following PARP inhibition in ovarian cancer (OC) patients at Mount Vernon Cancer Centre.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 49P – First Report on Pan-Immune-Inflammation Value as a New Prognostic Factor in Ovarian Cancer A Biomarker Analysis of OVANORDEST-1 Study.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 4P – Evaluation of Antitumor Activity and Immunogenic Cell Death (ICD) Induction.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 50P – Can We Learn From Failures A Systematic Review and Metanalysis of Phase III Trials in Platinum Resistant Ovarian Cancer.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 51P – Efficacy of PARP inhibitors in patients with advanced high grade serous ovarian cancer according to BRCA domain mutations.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 52P – Real world data of Niraparib in platinum sensitive relapsed ovarian cancer a multicenter experience of the MITO group.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 53P – Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 54P – Fallopian tube cancer and ovarian cancer A real-world comparison of epidemiological patterns, clinical outcomes, and mutational landscape.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 55P – Evolution of Genetic Testing after Ovarian Cancer (OC) diagnosis.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 56P – Differential response to DNA damaging agents of patients carrying the germline BRCA1 c.211 A-G pathogenic variant.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 57P – International Ovarian Tumor Analysis (IOTA) Simple Ultrasound Rules and Risk of Malignancy Index in differentiating benign.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 58P – The lymphocyte activation gene-3 (LAG-3) protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 59P – Expression of CD47 a potent `don’t eat me’ signal’ in ovarian cancer (OC)- Correlation with other immune features and evolution under neoadjuvant.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 5P – Physiologically relevant treatment models to investigate epigenetic mechanisms driving platinum.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 60P – Deciphering CD8+ T-cell-related gene signatures in the tumor microenvironment to predict the immunotherapy response and prognosis.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 61P – Fluorescent detection of epithelial cells in intraoperative flushes in ovarian cancer in the liquid biochip format.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 62P – Development of deep learning-based auto-segmentation algorithms to diagnose and indicate peritoneal carcinomatosis lesions of ovarian cancer.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 63P – Redefining the role of CA 19-9 as a prognostic marker in Epithelial Ovarian Cancer.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 64P – Malignant Brenner Tumor of the Ovary- impact of adjuvant chemotherapy, age, race, laterality and stage on survival outcome.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 65P – Clinical outcomes in ovarian clear cell carcinoma A UK single centre experience.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 66P – PD-L1 expression following neoadjuvant chemotherapy is upregulated and serves as a prognostic factor.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 67P – Survival and reproductive outcomes of patients with malignant ovarian germ cell tumors, a retrospective analysis.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 68P – Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement).pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 69P – Relationship between BRCA genotype by location and duration of response to iPARP treatment. Real-life data.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 6P – Unveiling the impact of intra-tumor heterogeneity in treatment response to achieve personalized medicine.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 70P – Prognostic factors and outcome in ovarian adult granulosa-cell tumours a retrospective real-world data.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 71P – survival outcomes of patients with recurrent malignant ovarian germ cell tumors, a retrospective analysis from a tertiary cancer center.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 72TiP – AVALON Trial Phase 2b Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects with Platinum-Resistant.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 73TiP – Niraparib maintenance in first line ovarian cancer MITO 40 an observational real-life study.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 75P – Clinical characteristics and Desensitization protocol of Chemotherapy-induced Hypersensitivity reactions in patients with gynecologic cancer.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 76P – To do or not to do Endometrial biopsy in younger women with abnormal uterine bleeding.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 77P – The impact of COVID-19 on gynecological cancer diagnoses in Greece.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 78P – Electronic tool for high grade Adverse Event (AE) reporting in gynecology (gyne) clinical trials (ClinT) at Princess Margaret Cancer Centre (PM).pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 79P – The situation of gynecological cancer before and after COVID – 19 pandemic years in Kosovo.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 7P – Integration of whole genome sequencing (WGS) into NHS pathways for high-grade ovarian cancer (HGOC).pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 80P – Efficacy, FDA approval, innovativeness, clinical evidence, and price of breast, ovarian, endometrial, and cervical cancer drugs.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 8P – NXP800 versus cisplatin in ARID1a-mutated Ovarian Clear Cell Carcinoma xenograft models.pdf\u003c\/li\u003e\n\u003cli\u003ePoster Display session 9P – The Survival Effect And Prognost-c Factors Of Residual Tumor Conf.pdf\u003c\/li\u003e\n\u003cli\u003eProffered Paper session 32O – 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts).mp4\u003c\/li\u003e\n\u003cli\u003eProffered Paper session 32O – 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts).pdf\u003c\/li\u003e\n\u003cli\u003eProffered Paper session 33O – PRIMA ENGOT-OV26 GOG-3012 study long-term conditional PFS.mp4\u003c\/li\u003e\n\u003cli\u003eProffered Paper session 33O – PRIMA ENGOT-OV26 GOG-3012 study long-term conditional PFS.pdf\u003c\/li\u003e\n\u003cli\u003eProffered Paper session 34O – ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss.mp4\u003c\/li\u003e\n\u003cli\u003eProffered Paper session 34O – ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss.pdf\u003c\/li\u003e\n\u003cli\u003eProffered Paper session 35O – Overall Survival of Niraparib with Individualized Starting Dose as Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer.mp4\u003c\/li\u003e\n\u003cli\u003eProffered Paper session 35O – Overall Survival of Niraparib with Individualized Starting Dose as Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer.pdf\u003c\/li\u003e\n\u003cli\u003eProffered Paper session Invited Discussant of abstract 34O.mp4\u003c\/li\u003e\n\u003cli\u003eProffered Paper session Invited Discussant of abstract 34O.pdf\u003c\/li\u003e\n\u003cli\u003eProffered Paper session Invited Discussant of abstract 35O.mp4\u003c\/li\u003e\n\u003cli\u003eProffered Paper session Invited Discussant of abstract 35O.pdf\u003c\/li\u003e\n\u003cli\u003eProffered Paper session Invited Discussant of abstracts 32O and 33O.mp4\u003c\/li\u003e\n\u003cli\u003eProffered Paper session Invited Discussant of abstracts 32O and 33O.pdf\u003c\/li\u003e\n\u003cli\u003eProffered Paper session Q\u0026amp;A and discussion.mp4\u003c\/li\u003e\n\u003cli\u003eRare cancers Introduction.mp4\u003c\/li\u003e\n\u003cli\u003eRare cancers Is immune therapy definitely required for all clear cell carcinoma.mp4\u003c\/li\u003e\n\u003cli\u003eRare cancers Is immune therapy definitely required for all clear cell carcinoma.pdf\u003c\/li\u003e\n\u003cli\u003eRare cancers Q\u0026amp;A.mp4\u003c\/li\u003e\n\u003cli\u003eRare cancers State-of-the-art management in carcinosarcoma From the biology to treatment.mp4\u003c\/li\u003e\n\u003cli\u003eRare cancers State-of-the-art management in carcinosarcoma From the biology to treatment.pdf\u003c\/li\u003e\n\u003cli\u003eRare cancers Which drugs could be relevant for LGSC The present and future.mp4\u003c\/li\u003e\n\u003cli\u003eRare cancers Which drugs could be relevant for LGSC The present and future.pdf\u003c\/li\u003e\n\u003cli\u003eRegeneron – VELOCISUITE- Leveraging Regeneron’s technologies to produce an innovative therapeutic pipeline.mp4\u003c\/li\u003e\n\u003cli\u003eSeagen – Driving towards the future Key messages and close.mp4\u003c\/li\u003e\n\u003cli\u003eSeagen – Driving towards the future Welcome and introduction.mp4\u003c\/li\u003e\n\u003cli\u003eSeagen – Driving towards the future What has changed and what’s next in the 1L setting for r_m CC-.mp4\u003c\/li\u003e\n\u003cli\u003eSeagen – Driving towards the future What’s new and how can we improve 2L management of r_m CC-.mp4\u003c\/li\u003e\n\u003cli\u003eWelcome from the Congress Chairs Do we still need radical surgery in the PARP inhibitor era.mp4\u003c\/li\u003e\n\u003cli\u003eWelcome from the Congress Chairs Do we still need radical surgery in the PARP inhibitor era.pdf\u003c\/li\u003e\n\u003cli\u003eWelcome from the Congress Chairs How to select the best first line maintenance treatment.mp4\u003c\/li\u003e\n\u003cli\u003eWelcome from the Congress Chairs How to select the best first line maintenance treatment.pdf\u003c\/li\u003e\n\u003cli\u003eWelcome from the Congress Chairs Introduction.mp4\u003c\/li\u003e\n\u003cli\u003eWelcome from the Congress Chairs New treatment in the current ovarian cancer beyond ADCs.mp4\u003c\/li\u003e\n\u003cli\u003eWelcome from the Congress Chairs New treatment in the current ovarian cancer beyond ADCs.pdf\u003c\/li\u003e\n\u003cli\u003eWelcome from the Congress Chairs PARP inhibitors Mechanism of resistance and how to overcome.mp4\u003c\/li\u003e\n\u003cli\u003eWelcome from the Congress Chairs PARP inhibitors Mechanism of resistance and how to overcome.pdf\u003c\/li\u003e\n\u003cli\u003eWelcome from the Congress Chairs Q\u0026amp;A.mp4\u003c\/li\u003e\n\u003cli\u003eWelcome from the Congress Chairs Welcome to the ESMO Gynaecological Cancers Congress 2023.mp4\u003c\/li\u003e\n\u003cli\u003eWelcome from the Congress Chairs Welcome to the ESMO Gynaecological Cancers Congress 2023.pdf\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954346987618,"sku":"MED-AMB01658","price":50.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/European-Society-for-Medical-Oncology-Gynaecological-Cancers-Congress-2023-1.jpg?v=1779374401","url":"https:\/\/meducourse.com\/products\/the-esmo-gynaecological-cancers-congress-2023","provider":"Meducourse","version":"1.0","type":"link"}